S1B 408
Alternative Names: S1B-408Latest Information Update: 28 Sep 2024
At a glance
- Originator S1 Biopharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anorgasmia
Most Recent Events
- 31 Jul 2024 Preclinical trials in Anorgasmia in USA (unspecified route)
- 25 Jul 2024 S1 Biopharma plans a phase IIa trial for Anorgasmia (NCT06516055)